OSLO, Norway, April 10, 2019 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-05 clinical trial of single-administration Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large …

Source: https://www.prnewswire.com:443/news-releases/nordic-nanovector-safety-review-committee-approves-advancing-to-final-dosing-regimen-in-phase-1-trial-of-betalutin-in-dlbcl-300829652.html

This entry was posted on Wednesday, April 10th, 2019 at 12:22 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.